Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6068 participants.
Also called NCT01147250
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,068 participants
- Sponsor
- Registry
-
NCT01147250 -
2009-012852-26
-
- Other papers using this trial's data
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
- Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Guatemala, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway, Panama, Peru, Philippines, Poland, Portugal, Romania, Russia, Serbia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Türkiye, Ukraine, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01147250. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
- Acronym
- ELIXA
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01147250- Content hash
60c99e17a3b9d80ab11367e4df2b1d36d2657b5561819f602a268e4ec3c60624